Watch AARD. Know when insiders buy.
One email the day a filing lands. Free.
AARD
Aardvark Therapeutics, Inc.
5.38
−0.35 −6.11%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
67
PASS · shorts 67
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $117.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$69.9MNET CASH —52W 3.48 – 17.41SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$15.1M | −$14.4M | — | -0.66 | −$17.6M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$22.5M | −$21.6M | — | -0.99 | −$18.9M | — | — | May 7 |
| Q4 2025 · Dec 31derived | — | — | — | −$18.7M | −$17.6M | — | -0.81 | −$16.8M | $0 | −$16.8M | Mar 23 |
| Q3 2025 · Sep 30 | — | — | — | −$17.7M | −$16.3M | — | -0.75 | −$16.1M | $4K | −$16.1M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$15.8M | −$14.4M | — | -0.66 | −$9.8M | $91K | −$9.9M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$10.5M | −$9.3M | — | -0.71 | −$11.4M | $0 | −$11.4M | May 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$9.4M | −$8.8M | — | -2.18 | −$7.7M | $6K | −$7.7M | Mar 23 |
| Q3 2024 · Sep 30 | — | — | — | −$5.1M | −$4.2M | — | -1.05 | −$4M | $5K | −$4M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$6.1M | −$5.4M | — | -1.37 | −$4.2M | $93K | −$4.3M | Aug 13 |
| Q1 2024 · Mar 31 | — | — | — | −$2.2M | −$2.2M | — | -0.55 | −$2.2M | $5K | −$2.2M | May 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$62.7M | −$57.6M | — | -2.93 | −$54.2M | $95K | −$54.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$22.8M | −$20.6M | — | -5.15 | −$18.1M | $109K | −$18.2M | — | — |
Every number comes from Aardvark Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.